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Abstract: Irbesartan, an angiotensin II type 1 receptor antagonist, is approved as monotherapy, 
or in combination with other drugs, for the treatment of hypertension in many countries world-
wide. Data in the literature suggest that irbesartan is effective for reducing blood pressure over 
a 24-hour period with once-daily administration, and slows the progression of renal disease in 
patients with hypertension and type 2 diabetes. Furthermore, irbesartan shows a good safety 
and tolerability profile, compared with angiotensin II inhibitors and other angiotensin II type 1 
receptor antagonists. Thus, irbesartan appears to be a useful treatment option for patients with 
hypertension, including those with type 2 diabetes and nephropathy. Irbesartan has an inhibi-
tory effect on the pressor response to angiotensin II and improves arterial stiffness, vascular 
endothelial dysfunction, and inflammation in hypertensive patients. There has been considerable 
interest recently in the renoprotective effect of irbesartan, which appears to be independent of 
reductions in blood pressure. In particular, mounting data suggests that irbesartan improves 
endothelial function, oxidative stress, and inflammation in the kidneys. Recent studies have 
highlighted a possible role for irbesartan in improving coronary artery inflammation and vascular 
dysfunction. In this review we summarize and comment on the most important data available 
with regard to antihypertensive effect, endothelial function improvement, and cardiovascular 
risk reduction with irbesartan.
Keywords: blood pressure, hypertension, endothelial function, irbesartan, antihypertensive 
drugs, combination therapy
Introduction
Hypertension and cardiovascular risk
Several studies have shown that elevated blood pressure (BP) is a major risk factor for 
cardiovascular morbidity and mortality. This relationship is strong and continuous in 
a range of patient populations and age groups.1–5 Most of the major guidelines for the 
treatment of hypertension recommend that individuals with a BP $ 140/90 mmHg 
should be regarded as hypertensive, and treated in order to keep BP below this 
threshold. Systolic BP and diastolic BP (SBP and DBP, respectively) targets gener-
ally must be lower in patients at high cardiovascular risk and in those with diabetes 
or renal disease.6,7
Nearly 40 years ago, data from the Framingham Heart Study showed that SBP was 
more closely associated with the risk of cardiovascular disease than DBP. Although 
DBP was shown to be a more useful predictor of cardiovascular risk in hypertensive 
patients younger than 45 years, for the majority of hypertensive patients, the ability 
of SBP to predict ischemic cardiovascular disease was not improved by addition of Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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DBP data. The superior predictive ability of SBP was more 
recently confirmed by the Prospective Studies Collaboration, 
a meta-analysis of 61 prospective observational studies that 
recorded BP and cause-specific mortality.5 In this study, 
Lewington et al found that SBP at baseline was more infor-
mative than DBP as a predictor of stroke and mortality from 
ischemic heart disease. Moreover the study concluded that, in 
middle-aged individuals, prolonged reductions in usual SBP 
of only 2 mmHg would lead to substantial reductions in the 
incidence of death secondary to stroke (a 7% reduction) and 
other vascular causes (10%).5,11
These data are supported by those of Stamler et al who 
found that SBP had a stronger association with cardiovascular 
risk than DBP in middle-aged and elderly individuals. At 
every level of DBP in this population, a higher SBP value 
was associated with greater cardiovascular risk and lower 
life expectancy.12
Recently, Benetos et al aimed to determine whether the 
high cardiovascular mortality rate in treated hypertensive 
patients was due to hypertension or to the presence of associ-
ated risk factors and/or diseases. Using cardiovascular mor-
tality data from treated hypertensive patients (n = 8893) and 
from untreated age- and gender-matched normotensive and 
hypertensive controls (n = 25,880) enrolled in the Investiga-
tions Préventives et Cliniques cohort, Benetos et al observed 
that the two-fold increase in cardiovascular and coronary 
mortality found in treated hypertensive patients persisted after 
adjustment for cardiovascular risk factors. Adjustment for SBP 
was necessary to make the mortality rates similar in the two 
populations. Subsequent inclusion of DBP in the model did not 
modify the between-group risk ratio. These results suggest that 
the increased cardiovascular mortality in treated hypertensive 
patients is mainly due to uncontrolled SBP levels.13
Moreover, the incidence of most adverse cardiovascular 
events appears to follow a circadian pattern, reaching a peak 
in the morning shortly after waking and arising. The activ-
ity of many physiologic parameters fluctuates in a cyclical 
manner over 24 hours. It has been suggested that, during the 
post-awakening hours, the phases of hemodynamic, hema-
tologic, and humoral cycles synchronize, thus creating an 
environment that predisposes to atherosclerotic plaque rup-
ture and thrombosis in susceptible individuals. BP and heart 
rate follow a clear circadian rhythm. The increased SBP and 
DBP in the morning may act as a trigger for cardiovascular 
events, including myocardial infarction and stroke. The clini-
cal implication of these observations is that antihypertensive 
therapy should provide BP control over the entire interval 
between doses.14
There is strong evidence that sustain the high variability 
of BP over 24 hours.15 Furthermore, data from cross-sectional 
studies16 suggest that target organ damage is greater in hyper-
tensive persons with high BP variability. The daytime SBP 
variability is a strong predictor of early carotid atherosclerosis 
progression and is useful to define the risk-benefit ratio of 
therapeutic approaches. A major impact of circadian BP 
patterns on the development of early carotid atherosclerosis 
has been demonstrated.17,18
endothelial physiology and dysfunction
Until a few years ago, the endothelium was considered to 
be just a cellular barrier between circulating blood and the 
arterial muscle wall, and was thought to be involved only 
in the processes of transport, metabolism, and coagulation. 
However, it has now been demonstrated that most of the 
pathophysiologic mechanisms that lead to atherosclerosis 
are located in the endothelium.19 The physiologic vascu-
lar action of the endothelium is modulated by a series of 
molecules controlling vasodilation and, to a minor extent, 
vasoconstriction.20 There is mounting evidence to suggest 
that hypertension is associated with endothelial abnormalities 
that are not likely to be related to high BP values, and more 
to hypertension per se.21
Accordingly, endothelial dysfunction is not only improved 
by reduction of BP values, but may also be improved by phar-
macologic treatment for hypertension.22 The mean feature 
of endothelium-mediated vasodilatation in hypertensive 
patients is the reduced availability of nitric oxide (NO). In 
patients with essential hypertension, activation of endothe-
lial cells induces production of cyclo-oxygenase-dependent 
factors, such as free radicals, which are responsible for the 
impaired bioavailability of NO. When cyclo-oxygenase 
activity is blocked, the bioavailability of NO is immediately 
restored. In hypertensive patients, vitamin C infusion is able 
to improve acetylcholine (Ach)-induced vasodilatation.23
NO bioavailability is usually decreased either by 
decreased formation or by enhanced removal. The pres-
ence of classic cardiovascular risk factors is associated with 
enhanced generation of radical oxygen species. Superoxide 
anions (O2−) play a pivotal role by reacting with NO, result-
ing in the formation of peroxynitrite (ONOO−), and hence 
decreasing bioavailability of NO.24 Studies with simultane-
ous measurement of relaxation and release of NO clearly 
show that endothelial cell signal transduction is altered in 
hypertension.25
Moreover, in studies with healthy human subjects, 
several agonists (including Ach and bradykinin) have been Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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found to induce vasodilation when injected directly into 
the brachial or coronary circulation.26–28 This vasodilation 
appears mainly regulated by specific NO synthase inhibitors, 
such as Nv-monomethyl-larginine (L-NMMA). In patients 
with essential hypertension, the response to endothelium-
dependent agonists (mainly Ach or bradykinin) is blunted 
in different vascular regions when compared with healthy 
controls. This diminished relation response to Ach or bra-
dykinin is, moreover, resistant to L-NMMA, which suggests 
the presence of compromised NO availability caused mainly 
by oxidative stress.29–32
Some authors suggest that chronic inflammation may play 
a significant role in hypertension. A persistent low-grade 
inflammatory state could be associated with increased levels 
of cytokine plasma concentration. By impairing the capacity 
of the endothelium to generate vasodilating factors, particu-
larly NO, elevated cytokines may lead to the development of 
endothelial dysfunction, chronically impaired vasodilation, 
and hypertension.33
Other studies suggest that endothelial dysfunction may 
be reversible. Physical exercise, calcium channel blockers 
(CCBs), angiotensin-converting enzyme inhibitors (ACEIs), 
and angiotensin receptor antagonists (ARBs) are effective in 
improving flow-stimulated endothelium-dependent vasodila-
tion in patients with hypertension and diabetes mellitus.34,35
The ARB irbesartan shows high efficacy in lowering 
BP, to a degree comparable with ACEIs and superior to 
other ARBs, including losartan and valsartan. Moreover, 
irbesartan has been shown to be effective in both early- 
and late-stage diabetic nephropathy.36 Irbesartan has 
furthermore demonstrated considerable cost savings over 
standard therapy, including beta-blockers, diuretics, and 
nondihydropyridine CCBs in all stages of kidney disease. 
Efficacy data from the Irbesartan Diabetic Nephropathy 
Trial and Reduction of Endpoints with the Angiotensin II 
Antagonist Losartan Study37 has also demonstrated better 
cost savings with irbesartan than losartan in late-stage renal 
disease. While both irbesartan and losartan are registered for 
the treatment of late-stage diabetic nephropathy, irbesartan 
is also registered for early-stage diabetic nephropathy in 
the European Union. Some investigators claim there is a 
genuine value in using irbesartan instead of other ARBs in 
the treatment of hypertension,38 and there is strong evidence 
of a positive impact from irbesartan in the treatment of 
hypertensive patients with endothelium-dependent vaso-
dilation.39 This effect is partially shared with other ARBs, 
although the specific activity of irbesartan has been shown 
in experimental studies.40
Pharmacology
Irbesartan is nearly completely absorbed following oral 
administration, with an average absolute bioavailability of 
60%–80%. About 25% of an administered radioactive dose 
is excreted in the urine and the remainder is eliminated in 
feces.41 Several determinants of drug disposition, such as gas-
tric acidity, gastric motility, glomerular filtration rate, plasma 
albumin, and renal and hepatic blood flow are altered in 
elderly subjects.42 It is possible that one or more factors may 
contribute to the observed significant increases in the Cmax 
and AUC of irbesartan. Results obtained in renally impaired 
patients indicated that renal impairment had no clinically 
important effects on the pharmacokinetics of irbesartan.43 
Food does not affect the bioavailability of irbesartan, so it can 
be administered without regard to meals.44 Although there is 
an effect of age on the pharmacokinetics of irbesartan, based 
on the safety and efficacy profile, no adjustment in irbesartan 
dosage is necessary with respect to age or gender.45
Irbesartan is a selective antagonist for the angiotensin II 
type 1 (AT1) receptor. The irbesartan concentration needed to 
reduce specific binding of 125I-angiotensin II to rat adrenal 
cortical microsomes by 50% is 0.9 nmol/L. Irbesartan has 
no active metabolites.46
Efficacy studies of irbesartan
effects on blood pressure
The effects of ARBs on hypertension are well known from 
the literature, and the efficacy of irbesartan in lowering BP 
is evident both in experimental and clinical studies.47 All 
irbesartan regimens significantly reduced mean 24-hour 
ambulatory BP values and were well tolerated. Administra-
tion of irbesartan 150 mg once a day provides significant 
reduction of BP for 24 hours, equivalent to that obtained with 
the same total daily dose divided into two doses.48
The antihypertensive effect of irbesartan on both SBP 
and DBP appears increased when administered in combina-
tion with diuretics. In a study by Mugellini et al, reduction 
of DBP and SBP with irbesartan-hydrochlorothiazide was 
comparable with that obtained with manidipine-delapril 
(−26.4/20.2 mmHg and −27.6/21.8 mmHg, respectively) 
and better than that of the respective monotherapies 
(−16.3/11.3 mmHg with delapril and −15.2/11.7 mmHg 
with irbesartan) in hypertensive patients with type 2 diabetes 
mellitus.49
Recently, an uncontrolled, multicenter study has con-
firmed the efficacy of the combination of irbesartan and 
hydrochlorothiazide.50 The aim of this large study was to com-
pare the antihypertensive efficacy of valsartan 80 mg versus Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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irbesartan 150 mg when combined with   hydrochlorothiazide 
12.5 mg. Untreated or uncontrolled hypertensive adults 
(n = 800) were enrolled by primary care physicians. After 
a five-week, open-label, lead-in phase in which all patients 
received 12.5 mg hydrochlorothiazide once daily, subjects 
whose BP remained uncontrolled (n = 464) were randomized 
to valsartan-hydrochlorothiazide (80/12.5 mg) or irbesartan-
hydrochlorothiazide (150/12.5 mg). After eight weeks, the 
irbesartan-hydrochlorothiazide combination produced greater 
reductions in average SBP and DBP measured by home BP 
monitoring than did valsartan-  hydrochlorothiazide (SBP 
−13.0 versus −10.6 mmHg, P = 0.0094; DBP −9.5 versus 
−7.4 mmHg, P = 0.0007, respectively). Comparable results 
were obtained between the groups for clinic BP measure-
ments. The overall drug safety was similar between the two 
treatment groups.51
An irbesartan-hydrochlorothiazide fixed-dose combina-
tion has been approved for clinical use, and its efficacy and 
safety has recently been evaluated in a study of 96 hyperten-
sive diabetic patients randomized to 12 months of double-
blind treatment with doxazosin 4 mg/day or irbesartan 
300 mg/day.52 At the end of the study, SBP and DBP were 
significantly (P , 0.01) reduced from 152 to 140 mmHg 
and from 97 to 87 mmHg, respectively, with doxazosin. SBP 
and DBP were reduced from 150 to 134 mmHg and from 
94 to 83 mmHg, respectively, with irbesartan (P , 0.01). 
Irbesartan had significantly better antihypertensive efficacy 
than doxazosin (P , 0.05).53 In patients with increased DBP, 
irbesartan shows comparable efficacy to that of amlodipine. 
In a study of non-African-American patients with a seated 
DBP of  95–100 mmHg, irbesartan 150 mg/day did not show 
any significant difference in DBP-lowering effect compared 
with amlodipine 5 mg/day.54
In a recent study by Fogari et al, 94 hypertensive patients 
were randomized to valsartan 160 mg + amlodipine 5 mg 
or irbesartan 300 mg + hydrochlorothiazide 12.5 mg for 
24 weeks after a four-week placebo period. Both combina-
tions significantly reduced clinical seated and lying BP val-
ues, with no difference between treatments. BP changes from 
the lying to standing position were significantly greater in the 
irbesartan-hydrochlorothiazide group (−17.2/−9.1 mmHg) 
than in the valsartan-amlodipine group (−10.1/−1.9 mmHg, 
P , 0.05 for SBP and P , 0.01 for DBP versus irbesartan-
hydrochlorothiazide). Both combinations were similarly 
effective in reducing ambulatory and clinical BP in very 
elderly hypertensive subjects.55
Compared with ACEIs, irbesartan has a similar effect 
on BP reduction, with fewer adverse events recorded 
for   irbesartan. In a double-blind, randomized study, an 
irbesartan-based antihypertensive regimen reduced SBP/
DBP by 40/30 mmHg after 12 weeks in patients with severe 
hypertension. This reduction was at least equivalent to that 
of a regimen using enalapril up to 40 mg. The irbesartan-
based regimen had a better tolerability profile with fewer 
adverse events (55% versus 64%) and significantly less cough 
(2.5% versus 13.1%, P = 0.007).56 These results have been 
confirmed in a larger clinical trial comparing irbesartan and 
enalapril. Two hundred and thirty-eight patients were ran-
domized to treatment, and the study was completed by 111 
patients in the irbesartan group (dose titrated to 300 mg/day 
in 72.0% of patients) and 115 patients in the enalapril group 
(dose titrated to 20 mg/day in 76.5% of patients). BP reduc-
tions were similar in the two groups, both as measured in 
the clinic (DBP −12.7 ± 8.8 mmHg for irbesartan versus 
−12.4 ± 7.4 mmHg for enalapril; SBP −19.0 ± 14.1 mmHg 
versus −17.5 ± 14.0 mmHg, respectively) and by 24-hour 
ambulatory BP monitoring (DBP −9.4 ± 8.5 mmHg 
  versus −8.8 ± 8.5 mmHg; SBP −14.7 ± 14.7 mmHg versus 
−12.6 ± 13.1 mmHg). The overall incidence of adverse events 
(40.0% for irbesartan, 51.2% for enalapril) was not statisti-
cally different between the treatment groups, although the 
incidence of adverse events, probably related to antihyper-
tensive treatment, was significantly higher with enalapril than 
with irbesartan (24.6% versus 9.2%, respectively, P = 0.026), 
and were essentially accounted for by a higher incidence of 
cough (8.1% versus 0.9%, respectively).57
Compared with other ARBs, irbesartan shows equal or 
greater efficacy in reducing both SBP and DBP. In a study 
by Mancia et al, irbesartan was more effective than valsartan 
in reducing DBP and SBP at trough levels and in providing 
greater overall 24-hour BP lowering. In another study, after 
a three-week, single-blind, placebo lead-in period, 426 sub-
jects were randomized to receive either irbesartan 150 mg or 
valsartan 80 mg for eight weeks. At the end of the study, irbe-
sartan provided significantly greater reductions than valsartan 
for mean change from baseline in diastolic ambulatory BP at 
trough (−6.73 versus −4.84 mmHg, respectively, P = 0.035) 
and in mean systolic ambulatory BP at trough (−11.62 versus 
−7.5 mmHg, respectively, P , 0.01). Similar results were 
obtained for mean 24-hour diastolic ambulatory BP (−6.38 
versus −4.82 mmHg, respectively, P = 0.023) and systolic 
ambulatory BP (−10.24 versus −7.76 mmHg, P , 0.01). 
Irbesartan also produced significantly greater reductions 
than valsartan for office-measured seated DBP (−10.46 
versus −7.28 mmHg, respectively, P , 0.01) and SBP 
(−16.23 versus −9.96 mmHg, respectively, P , 0.01) and Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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for   self-measured morning DBP (−6.28 versus −3.75 mmHg, 
respectively, P , 0.01) and SBP (−10.21 versus −6.97 mmHg, 
respectively, P , 0.01).58
effects on vascular endothelium
Recent findings suggest that AT1 receptor blockade improves 
superoxide production and NO bioavailability more than 
do other classes of antihypertensive agents. In a study by 
Brosnan et al, in vivo irbesartan, amlodipine, and hydro-
chlorothiazide-hydralazine produced similar reductions 
in BP values, but irbesartan caused a greater reduction in 
superoxide and p22phox in carotid arteries. Four-hour in vitro 
exposure to irbesartan decreased superoxide levels in the 
aorta and increased NO bioavailability in carotid   arteries. 
Neither 30-minute incubation with irbesartan nor four hours 
with amlodipine or hydrochlorothiazide-hydralazine altered 
superoxide levels. Reduced expression of components of 
nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase may contribute to these effects.59
Moreover, a protective effect of AT1 receptor blockers on 
endothelial function during postprandial hypertriglyceridemia 
has been reported in healthy subjects.60 In 2005, Ceriello et al 
demonstrated, for the first time, that irbesartan, like statins, 
is able to ameliorate the damage done to endothelial function 
by postprandial hyperglycemia and hypertriglyceridemia, 
oxidative stress, and inflammation in diabetic patients. These 
results appeared not to be linked to the BP-lowering effect 
and were obtained after short-term treatment. In this study, 
combination treatment of atorvastatin and irbesartan showed 
a more powerful effect on vascular damage compared with 
monotherapy using irbesartan or atorvastatin.61
Pharmacodynamic data suggest that irbesartan at a dose of 
300 mg provides more effective and persistent AT1 blockade 
than losartan 100 mg. In a short-term (eight week) study by 
Kassler-Taub et al, after a placebo lead-in, 567 patients were 
randomized to once-daily therapy with placebo, losartan 
100 mg, irbesartan 150 mg, or irbesartan 300 mg. At the end 
of the study, reductions from baseline in seated DBP and 
seated SBP with irbesartan 300 mg were greater than those 
obtained with losartan 100 mg by −3.0 and −5.1 mmHg, 
respectively (P , 0.01 for both comparisons). Larger reduc-
tions were also demonstrated at weeks 1 and 4 (P , 0.01 
and P = 0.017, respectively, for DBP and SBP) of the study, 
and the antihypertensive effects of the treatments were not 
significantly different.62
The renoprotective effect of irbesartan has been tested 
in a study by Rossing et al. In this study, 52 hypertensive 
patients with type 2 diabetes and microalbuminuria already 
on antihypertensive treatment were included. After a two-
month wash-out of other drugs, patients were randomized 
to receive irbesartan 300, 600, and 900 mg once daily. After 
a 10-week treatment period, ultrahigh doses of irbesartan 
were well tolerated and provided additional renoprotection 
independent of changes in BP values and glomerular filtration 
rate, compared with irbesartan 300 mg.63
Administration of irbesartan twice daily has been evalu-
ated in a study by Polónia et al who investigated whether 
blockage of angiotensin II receptors by irbesartan could 
reverse the nondipper circadian rhythm of BP to a dipper 
pattern in 12 black salt-sensitive hypertensive patients on 
a high sodium diet (300 mmol per day) after a two-week 
placebo administration, followed by two weeks on irbesar-
tan 150 mg/day, two weeks on placebo, and two weeks on 
irbesartan 300 mg/day. On the last day of placebo, and of the 
irbesartan 150 mg/day and irbesartan 300 mg/day treatments, 
24-hour BP and urinary 24-hour excretion of sodium and 
potassium were measured. Compared with placebo, irbe-
sartan significantly increased serum potassium and plasma 
renin activity and reduced fractional excretion of potassium 
and plasma aldosterone levels in a dose-dependent manner, 
without significant changes in body weight. The authors con-
cluded that irbesartan can reverse the nondipper BP profile 
in salt-sensitive hypertensive patients on a high-salt diet, 
restoring the nocturnal BP decline by a predominantly dose-
dependent reduction of night time BP. This result occurred 
independently of increased natriuresis. Evidence has been 
accumulating to suggest that ambulatory BP values are more 
strongly correlated with markers of cardiovascular disease 
than are clinic BP values.64
The main studies that showed a significant effect of irbe-
sartan in reducing microalbuminuria and decreasing the risk 
of diabetic nephropathy were Irbesartan Microalbuminuria 
type 2 Diabetes in Hypertensive Patients (IRMA II)65 and 
Irbesartan in Diabetic Nephropathy Trial (IDNT).66 These are 
two long-term (2–3 year) trials showing that the irbesartan 
is effective in reducing the progression of renal disease in 
patients with type 2 diabetes and high BP. In each trial, the 
standard of care for diabetes mellitus was maintained. Using 
conventional antihypertensive therapy, including diuretics, 
beta-blockers, and CCBs (but not ACEIs or other ARBs), 
BP control was similar in the placebo- and ARB-treated 
groups.
The IRMA II study (Table 1) evaluated the renoprotec-
tive effect of irbesartan, in hypertensive patients with type 2 
diabetes and microalbuminuria.65 This multinational, random-
ized, double-blind, placebo-controlled study enrolled a total Integrated Blood Pressure Control 2010:3
Table 1 The Irbesartan Microalbuminuria type 2 Diabetes in 
Hypertensive Patients II study
Title IRMA II (The Irbesartan MicroAlbuminuria type 2 
Diabetes in Hypertensive Patients Study)
Study Randomized, multicenter, placebo-controlled study
Design Three parallel groups of patients receiving 
irbesartan 150 mg/day, 300 mg/day, or placebo
Target BP ,135/85 mmHg after three months
Patients (n) 590
Patient  
characteristics
Type 2 diabetes 
Hypertension 
Microalbuminuria
Primary endpoint Onset of diabetic nephropathy in patients  
with type 2 diabetes 
Definition of diabetic nephropathy: 
urinary albumin excretion rate in an overnight  
specimen .200 μg/min and 30% of the baseline  
rate on at least two consecutive visits
Secondary  
endpoints
Changes in level of albuminuria 
Changes in creatinine clearance 
Restoration of normoalbuminuria 
Urinary albumin excretion rate in an overnight  
specimen 20 μg/min
Median follow-up  
treatment
2.0 years
Treatment  
dosages 
Irbesartan 150 mg/day (195 patients) 
Irbesartan 300 mg/day (194 patients) 
Placebo (201 patients)
Results  
(primary  
endpoint)
Nephropathy prevalence 
14.9% placebo group 
7.9% irbesartan 150 mg/daya 
5.2% irbesartan 300 mg/dayb,c 
Irbesartan 300 mg/day reduced the progression  
of diabetic nephropathy by 70%.
Results  
(secondary  
endpoints)
Urinary albumin excretion rate significantly  
decreased with irbesartan versus placebo (−38%  
in the irbesartan group)d 
Decline in creatinine clearance did not significantly  
differ between groups 
Average blood pressure 
–144/83 mmHg placebo 
–143/83 mmHg irbesartan 150 mg/day 
–141/83 mmHg irbesartan 300 mg/daye
Conclusions  Significant reduction of progression from  
microalbuminuria to nephropathy in diabetic  
patients treated with irbesartan, independently  
of BP control 
renoprotection independent of blood pressure 
reduction
aP = 0.08; bP , 0.001; cP , 0.001 for comparison between placebo and irbesartan 
300 mg/day; dP , 0.001 for irbesartan compared with placebo; eP = 0.004 for the 
comparison of systolic blood pressure between the combined irbesartan groups and 
the placebo group.
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of 590 hypertensive patients with type 2 diabetes and persis-
tent microalbuminuria who received irbesartan at a dose of 
either 150 mg daily or 300 mg daily, or placebo. The primary 
efficacy measure was the time from the baseline visit to the 
first detection of overt nephropathy, defined by a urinary albu-
min excretion rate in an overnight specimen .200 μg/min 
and at least 30% higher than the baseline rate on at least two 
consecutive visits. At the end of the study, nephropathy devel-
oped in 30 patients in the placebo group, compared with 19 
patients in the 150 mg irbesartan group and 10 patients in the 
300 mg irbesartan group. The unadjusted hazard ratio (HR) 
for diabetic nephropathy was 0.61 (P = 0.08) in the 150 mg 
group and 0.30 (P , 0.001) in the 300 mg group. The average 
BP during the course of the entire study was 144/83 mmHg 
in the placebo group, 143/83 mmHg in the 150 mg irbesartan 
group, and 141/83 mmHg in the 300 mg irbesartan group 
(P = 0.004 for the comparison of SBP between the placebo 
group and the combined irbesartan groups).
After adjustment for BP achieved during the study and 
the baseline level of microalbuminuria, the HR for diabetic 
nephropathy was 0.56 in the 150 mg group (P = 0.05) and 
0.32 in the 300 mg group (P , 0.001). Serious adverse events 
were less frequent among the patients treated with irbesartan 
(P = 0.02). Irbesartan reduced the level of urinary albumin 
excretion throughout the study. In the irbesartan 150 mg 
group, urinary albumin excretion decreased by 24% and, in 
the 300 mg group, decreased by 38%, whereas the placebo 
group had a 2% decrease (P , 0.001 for the comparison 
between placebo and combined irbesartan groups). There was 
a significantly smaller reduction in the level of albuminuria in 
the 150 mg group than in the 300 mg group (P , 0.001).
During this 24-month study, overt nephropathy developed 
in 30 patients in the placebo group, compared with 19 patients 
in the 150 mg group (P = 0.08) and 10 patients in the 300 mg 
group (P , 0.001). The unadjusted HR for diabetic neph-
ropathy was 0.61 (P = 0.08) in the 150 mg group and 0.30 
(P , 0.001) in the 300 mg group. After adjustment for the 
baseline level of microalbuminuria and the BP achieved dur-
ing the study, the HR for diabetic nephropathy was 0.56 in 
the 150 mg group (P = 0.05) and 0.32 in the 300 mg group 
(P , 0.001). At the three-month visit, the decrease in crea-
tinine clearance for the placebo group and the 300 mg irbe-
sartan group separated and continued to diverge. The decline 
in creatinine clearance during the initial three-month period 
was greater than the sustained decline from three months to 
24 months. The initial declines were 0.9, 1.0, and 1.9 in the 
placebo, and irbesartan 150 mg and 300 mg groups, respec-
tively, compared with declines of 0.1, 0.2, and 0.2 between 
months 3 and 24. Neither the initial decline nor the sustained 
decline differed significantly among the three groups. Irbesar-
tan reduced the level of urinary albumin excretion throughout 
the study. Urinary albumin decreased by 24% in the 150 mg 
group, 38% in the 300 mg group, and 2% in the placebo Integrated Blood Pressure Control 2010:3
Table 2 The IDNT study
Title IDNT (Irbesartan Diabetic Nephropathy Trial)
Study Prospective randomized, multicenter, double- 
blind placebo-controlled study
Design Groups were compared with regard to the time   
to the primary composite endpoint
Target BP 135/85 mmHg or less in all groups
Patients (n) 1.715
Patient  
characteristics
Type 2 diabetes 
Nephropathy due to type 2 diabetes
Primary endpoint Comparison between irbesartan and amlodipine   
efficacy in protection against the progression of  
nephropathy due to type 2 diabetes,  
independently of BP reduction
Secondary endpoints Overall mortality in the two treatment groups 
Rates of cardiovascular events in the two  
treatment groups
Treatments Irbesartan 300 mg/day 
Amlodipine 10 mg/day
Results 
(primary endpoint)
Irbesartan reduction of composite primary end- 
point 20% lower versus placebo and 23% versus   
amlodipinea,b 
Relative risk of doubling of serum creatinine  
concentration 33% lower with irbesartan versus   
placebo and 37% versus amlodipinec,d 
Relative risk of end-stage renal disease was 23%   
lower in irbesartan group than in both other  
groupse
Results (secondary 
endpoints)
No significant differences in the rate of death  
from any cause and in the cardiovascular  
composite endpoint
Conclusions  Significant reduction of progression from  
microalbuminuria to nephropathy in diabetic  
patients treated with irbesartan  
Renoprotection independent of blood pressure  
reduction
aP = 0.02 for irbesartan versus placebo; bP = 0.006 for irbesartan vs amlodipine; cP = 
0.003 for irbesartan versus placebo; dP , 0.001 for irbesartan versus amlodipine; 
eP = 0.07 for both comparisons.
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group (P , 0.001 for the comparison between placebo and 
the combined irbesartan groups). There was a significantly 
smaller reduction in the level of albuminuria in the 150 mg 
group than in the 300 mg group (P , 0.001).
In the other relevant large study, the IDNT66 compared the 
renoprotective effect of irbesartan and amlodipine in patients 
with type 2 diabetes and microalbuminuria (Table 2), beyond 
the effect of these two drugs on BP reduction. It was a pro-
spective, randomized, double-blind, placebo-controlled study 
including 1175 patients from 210 clinical centers. Patients 
enrolled in this study had hypertension and nephropathy 
due to type 2 diabetes. Patients were randomized to receive 
irbesartan 300 mg/day, amlodipine 10 mg/day, or placebo. 
Groups were compared according to time to the primary 
composite endpoint of a doubling of baseline serum creati-
nine concentration, development of end-stage renal disease, 
and death from any cause. The mean follow-up duration was 
2.6 years. At the end of the study, treatment with irbesartan 
was associated with a 20% and 23% reduction in risk of the 
primary composite endpoint compared with placebo and 
amlodipine, respectively (P = 0.006). The relative risk of 
doubling of the serum creatinine concentration was 33% 
and 37% lower in the irbesartan group compared with the 
placebo and amlodipine groups (P = 0.003 and P , 0.001, 
respectively). Treatment with irbesartan was associated with 
a significantly lower risk of end-stage renal disease (−23%) 
compared with that observed in the other groups (P = 0.07 
for both comparisons). These results were not affected by 
reduction in BP values. The increase in serum creatinine 
levels was slower in the irbesartan group compared with the 
placebo (−24%) and amlodipine (21%) groups (P = 0.008 and 
P = 0.002, respectively). No significant differences between 
groups were observed in the rate of death from any cause or 
in the cardiovascular composite endpoint.
Although the IRMA II and IDNT studies provided strong 
support for the beneficial effect of irbesartan in renoprotec-
tion, both studies included patients with hypertension who 
had been previously treated with antihypertensive drugs. In a 
short-term study, irbesartan was administered to newly diag-
nosed drug-naive patients; the effects of irbesartan 150 mg 
bid on microalbuminuria were observed in normotensive 
type 2 diabetic patients, suggesting that the renoprotective 
action of irbesartan is probably due to a direct action on renal 
hemodynamics and glomerular morphology.67
More recently, studies have demonstrated a precise 
role for irbesartan and statins in regulation of vascular dys-
function. In the Endothelial Protection, AT1 Blockade and 
Cholesterol-Dependent Oxidative Stress (EPAS) trial, the 
investigators showed that statin and AT1 blocker therapy 
independently and in combination improved both the antiath-
erosclerotic endothelial expression quotient and endothelial 
function. In this study, 60 patients with stable coronary artery 
disease undergoing elective coronary artery bypass graft-
ing surgery were randomized four weeks before surgery to 
no ARBs and/or statins (controls), pravastatin 40 mg/day, 
irbesartan 150 mg/day, or pravastatin in combination with 
irbesartan at the same dosages. The primary endpoint was 
a priori therapy-dependent regulation of the antiatheroscle-
rotic endothelial expression calculated marker of endothelial 
regulation. At the end of the study, association of irbesartan 
and pravastatin significantly improved endothelial   expression 
of antiatherosclerotic and proatherothrombotic genes and 
endothelial function in arteries in these patients with coro-Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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nary artery disease. Moreover, preoperative therapy with 
irbesartan and pravastatin and their combination improved 
endothelial function in internal mammary artery rings.68
Recently, many studies have focussed on molecular 
markers of the inflammatory mechanisms involved in athero-
genesis, and particular attention has been given to inflam-
matory molecules which interact with the endothelium, such 
as tumor necrosis factor-α, vascular cell adhesion molecule, 
and superoxides. In a study by Navalkar et al, irbesartan sig-
nificantly improved levels of inflammatory molecules in 33 
normotensive patients with coronary artery disease, and the 
maximal suppression of inflammatory markers was observed 
after 12 weeks.69 In another study, treatment with irbesartan 
was effective in reducing the pro-oxidative environment 
seen in patients with coronary artery disease. Lag time for 
LDL oxidation increased 32% at 12 weeks, suggesting that 
increased resistance of LDL modification during serum 
and lipid peroxidation decreased by 36% with irbesartan 
compared with placebo. In addition, superoxide levels and 
monocyte-binding capacity were also significantly reduced 
in coronary artery disease patients receiving irbesartan.70
Conclusions
Irbesartan is an angiotensin II receptor type 1 antagonist which 
has demonstrated significant efficacy in reducing BP in patients 
with high cardiovascular risk. In comparative trials, irbesartan 
seems significantly more effective than other ARBs in the 
treatment of mild to moderate essential hypertension, and is 
as effective as enalapril or atenolol. Many studies also show 
an additive antihypertensive effect when hydrochlorothiazide 
is added to irbesartan monotherapy. In hypertensive patients, 
the presence of an abnormal circadian BP rhythm as a result of 
lack of nocturnal BP decrease (nondippers) has been reported 
to be associated with a higher risk of cardiovascular end organ 
damage and a poorer prognosis for cardiovascular events 
compared with dippers (who show a normal nocturnal BP 
decrease). Irbesartan is able to modulate circadian BP rhythms 
and thereby significantly modifies the risk of organ damage due 
to hypertension and endothelial dysfunction, such as increased 
intima media thickness and left ventricular hypertrophy. Irbe-
sartan also induces statistically significant regression of left 
ventricular mass in patients with hypertension and left ven-
tricular hypertrophy, and preliminary evidence suggests it has 
beneficial hemodynamic effects in patients with heart failure.
Moreover, irbesartan counteracts a number of other 
defects that lead to high cardiovascular risk, in particular 
insulin resistance and endothelial dysfunction. The so-called 
ancillary effects of irbesartan, which are partially shared 
by other ARBs, have been highlighted in recent studies. 
Particular interest has arisen about the effects of irbesartan 
on vascular dysfunction, which represents one of the major 
mechanisms that lead to atherosclerosis, and metabolic and 
cardiovascular diseases. A beneficial effect of irbesartan on 
glomerular filtration and microalbuminuria has been estab-
lished in large clinical trials, such as IDNT and IRMA II. 
Many data suggest a relationship between BP and endothe-
lial dysfunction, so the role of irbesartan in modulation of 
vasodilatation and cytokines disorders could be explained in 
further experimental and clinical studies. Furthermore, the 
connection between insulin resistance, hypertension, and 
endothelial dysfunction, as well as the effects of ARBs on 
these mechanisms, has not been yet completely explained. In 
conclusion irbesartan is useful for clinicians for treatment of 
hypertension and prevention of organ damage, and appears 
well tolerated also at high dosage.
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